Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2021 | Enfortumab vedotin in urothelial cancer

Arlene Siefker-Radtke • 17 Feb 2021
GU Cancers 2021
Bladder Cancer Genitourinary Cancer Antibodies Enfortumab vedotin Taxane Vinflunine

Arlene Siefker-Radtke, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the use of the antibody-drug conjugate, enfortumab vedotin, for patients with urothelial cancer. A randomized trial showed overall improved response and survival rates in patients treated with enfortumab vedotin compared to taxane-based chemotherapy. In patient’s ineligible for front-line platinum-based therapy, enfortumab vedotin was active and tolerable, however it is essential to look out for toxicities. Patients with bone metastases also benefited from the use of enfortumab vedotin. This interview took place during the 2021 Genitourinary Cancers Symposium.

More from Arlene Siefker-Radtke

Current limitations and research on molecular subtyping in the treatment of urothelial carcinoma
1:11
Current limitations and research on molecular subtyping in the treatment of urothelial carcinoma
Arlene Siefker-Radtke • 31 May 2024
THOR: impact of FGFR3 alterations in mUC on subtype and outcomes with erdafitinib vs pembrolizumab
1:49
THOR: impact of FGFR3 alterations in mUC on subtype and outcomes with erdafitinib vs pembrolizumab
Arlene Siefker-Radtke • 31 May 2024
The role of enfortumab vedotin in urothelial cancer treatment
1:18
The role of enfortumab vedotin in urothelial cancer treatment
Arlene Siefker-Radtke • 31 May 2024
Phase III TROPICS-04 trial: sacituzumab govitecan vs treatment of choice in advanced mUC
1:13
Phase III TROPICS-04 trial: sacituzumab govitecan vs treatment of choice in advanced mUC
Arlene Siefker-Radtke • 31 May 2024

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals